Please try another search
Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.
Name | Age | Since | Title |
---|---|---|---|
Robert M. Littauer | 73 | 2004 | Independent Director |
Frederick B. Craves | 76 | 1993 | Director |
Richard M. Goldberg | - | - | Member of Clinical Advisory Board |
Alan B. Glassberg | 84 | 2004 | Member of Clinical Advisory Board |
Robert S. Basso | 77 | 2007 | Independent Director |
Skip Burris | - | 2008 | Member of Clinical Advisory Board |
E. David Crawford | - | 2008 | Member of Clinical Advisory Board |
Eric J. Small | - | - | Member of Clinical Advisory Board |
David R. Stevens | 73 | 2004 | Independent Director |
Paul A. Bunn | 76 | - | Member of Clinical Advisory Board |
Robert Ozols | - | 2008 | Member of Clincal Advisory Board |
Everett E. Vokes | 67 | 2008 | Member of Clinical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review